Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Withdrawn × Carcinoma × Ipilimumab × Clear all

Phase

Status

Completed 2 Active not recruiting 2 Withdrawn 1 Recruiting 1 Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Melanoma 13 Uterine Cervical Neoplasms 2 Prostatic Neoplasms 2 Neoplasm Metastasis 2 Hematologic Neoplasms 2 Colorectal Neoplasms 2 Carcinoma, Non-Small-Cell Lung 2 Xeroderma Pigmentosum 1 Vulvar Neoplasms 1 Vaginal Neoplasms 1 Uveal Melanoma 1 Turcot syndrome 1 Triple Negative Breast Neoplasms 1 Solid Tumor 1 Sarcoma 1 Neuroblastoma 1 Multiple Myeloma 1 Lymphoma 1 Lymphatic Metastasis 1 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1 Leukemia, Lymphocytic, Chronic, B-Cell 1 Hemangiosarcoma 1 Esophageal Neoplasms 1 Colorectal Neoplasms, Hereditary Nonpolyposis 1 Colonic Neoplasms 1 Central Nervous System Neoplasms 1 Carcinoma, Renal Cell 1 Carcinoma, Merkel Cell 1 Carcinoma 1 Breast Neoplasms 1

Interventions

Cisplatin 5 nimotuzumab 2 X-Rays 2 Radiotherapy 2 Magnetic Resonance Spectroscopy 2 trifluridine tipiracil drug combination 1 palladium-bacteriopheophorbide 1 padeliporfin 1 galactomannan 1 futuximab 1 cabozantinib 1 Tomography, Optical Coherence 1 Standard of Care 1 Specimen Handling 1 Ramucirumab 1 Radiotherapy, Intensity-Modulated 1 Radiotherapy, Image-Guided 1 Practice Guidelines as Topic 1 Platinum 1 Nivolumab 1 N-benzhydryl-5-(2-(methylamino)propanamido)-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo(1,2-a)(1,5)diazocine-8-carboxamide 1 Mitomycin 1 LMB-100 1 Ipilimumab 1 Interviews as Topic 1 Injections 1 Fluorouracil 1 Fluorodeoxyglucose F18 1 E-3810 1 Drug Delivery Systems 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04151563 2023-12-19

CheckMate 79X

Bristol-Myers Squibb

Phase 1/2 Withdrawn

Carcinoma, Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon ⚡